Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma have?
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma has 12 citations in the OpenAlex counts ScholarIQ stores.
When was Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma published?
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma has 2017 year in the ScholarIQ index.
What is the open-access status of Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma?
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma has closed oa status in the ScholarIQ index.
What is the DOI of Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma?
The DOI for Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma is on the source record.
What is the PMID of Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma?
The PMID for Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma is on the source record.
What is the OpenAlex record for Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma?
The OpenAlex for Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma is on the source record.